Biodesix Inc (BDSX) - Total Liabilities
Based on the latest financial reports, Biodesix Inc (BDSX) has total liabilities worth $90.44 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Biodesix Inc to assess how effectively this company generates cash.
Biodesix Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Biodesix Inc's total liabilities have evolved over time, based on quarterly financial data. See shareholders equity of Biodesix Inc for net asset value and shareholders' equity analysis.
Biodesix Inc Competitors by Total Liabilities
The table below lists competitors of Biodesix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
European Residential Real Estate Investment Trust
TO:ERE-UN
|
Canada | CA$515.33 Million |
|
Tradetool Auto Co Ltd
TWO:3685
|
Taiwan | NT$910.17 Million |
|
J W Mays Inc
NASDAQ:MAYS
|
USA | $36.28 Million |
|
meerecompany Incorporated
KQ:049950
|
Korea | ₩20.09 Billion |
|
Loxley Public Company Limited
F:NVAI
|
Germany | €6.74 Billion |
|
PP Presisi Tbk PT
JK:PPRE
|
Indonesia | Rp4.00 Trillion |
|
Consolidated Construction Consortium Limited
NSE:CCCL
|
India | Rs1.68 Billion |
|
Azaria Rental SOCIMI S.A.
MC:YAZR
|
Spain | €78.33 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Biodesix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Biodesix Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -52.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biodesix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biodesix Inc (2018–2024)
The table below shows the annual total liabilities of Biodesix Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $76.37 Million | -19.20% |
| 2023-12-31 | $94.52 Million | +30.73% |
| 2022-12-31 | $72.30 Million | +28.26% |
| 2021-12-31 | $56.37 Million | -29.45% |
| 2020-12-31 | $79.90 Million | -70.42% |
| 2019-12-31 | $270.17 Million | +13.95% |
| 2018-12-31 | $237.09 Million | -- |
About Biodesix Inc
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also pro… Read more